SYRE:NASDAQ
Spyre Therapeutics Inc
$95.51
arrow_downward
-1.09%(-1.05) 1D
$95.51
0.00% (0.00)
bedtimeAfter hours
Closed: Nov 2, 4:00:00 PM GMT-5 · USD
search
All symbols
No data
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for SYRE...
Open
$97.11
High
$98.13
Low
$93.82
Mkt. cap
8.80B
Avg. vol.
1.31M
Volume
752.07K
52-wk high
$110.18
52-wk low
$21.15
EPS
-$2.32
Beta
3.10
Shares outstanding
92.29M
No. of employees
125
Open
$97.11
High
$98.13
Low
$93.82
Mkt. cap
8.80B
Avg. vol.
1.31M
Volume
752.07K
52-wk high
$110.18
52-wk low
$21.15
EPS
-$2.32
Beta
3.10
Shares outstanding
92.29M
No. of employees
125
News stories
From web sources and news partners
Foreign Policy Journal
·
35 minutes ago
RTX Corporation's (NYSE: RTX) $271 Billion Backlog Fuels Analyst Optimism Despite Engine Concerns
Dealroom
·
39 minutes ago
Agility Robotics clears SPAC vote, expects $465M and Nasdaq debut November 5
investingLive
·
8 minutes ago
JPMorgan’s four midterm scenarios: S&P 500 seen moving between -0.25% and +1.25%
Bloomberg.com
·
4 hours ago
Nasdaq 100 Enters Correction as Megacap Results Amplify AI Fears
About Spyre Therapeutics Inc
CEO-
Employees125
FoundedJan 1, 2013
HeadquartersWaltham, Massachusetts, United States
SectorBiotechnology
Websitespyre.com
Analyst ratings
Based on 14 analysts giving stock ratings to SYRE in the past 3 months
Strong buy
Buy
14
Hold
0
Sell
0
12-month forecast
Based on 14 Wall Street analysts offering 12 month price targets for SYRE in the last 3 months.
Highest
Current $95.51
$130.00 (+36.11%)
Average
$122.00 (+27.74%)
Lowest
$110.00 (+15.17%)
Analyst | Recommendation | Action | Price target | Projected | Date |
|---|---|---|---|---|---|
Samantha Semenkow Citi | Buy | Maintained | $119.00 | +24.6% | 10/21/2026 |
Julian Harrison BTIG | Buy | Maintained | $121.00 | +26.7% | 10/19/2026 |
David Nierengarten Wedbush | Buy | Maintained | $123.00 | +28.8% | 10/19/2026 |
Unknown Analyst UBS | Buy | Initiated | $120.00 | +25.6% | 10/11/2026 |
Alice Nettleton UBS | Buy | Initiated | $120.00 | +25.6% | 10/12/2026 |
Yanan Zhu Wells Fargo | Buy | Maintained | $115.00 | +20.4% | 10/02/2026 |
Debanjana Chatterjee JonesTrading | Buy | Reiterated | $130.00 | +36.1% | 10/01/2026 |
Priyanka Grover J.P. Morgan | Buy | Initiated | $110.00 | +15.2% | 10/01/2026 |
Hardik Parikh J.P. Morgan | Buy | Initiated | $110.00 | +15.2% | 10/01/2026 |
Akash Tewari Jefferies | Buy | Maintained | $126.00 | +31.9% | 09/09/2026 |
Thomas Smith Leerink Partners | Buy | Reiterated | $128.00 | +34% | 09/10/2026 |
Sam Slutsky LifeSci Capital | Buy | Maintained | $116.00 | +21.5% | 09/08/2026 |
Yatin Suneja Guggenheim | Buy | Reiterated | $130.00 | +36.1% | 08/26/2026 |
David Hoang Deutsche Bank | Buy | Maintained | $127.00 | +33% | 08/26/2026 |
Alex Thompson CFA Stifel Nicolaus | Buy | Maintained | $123.00 | +28.8% | 08/13/2026 |
Colleen M. Kusy Robert W. Baird | Buy | Maintained | $120.00 | +25.6% | 08/05/2026 |
Andy Chen Wolfe Research | Hold | Downgraded | - | - | 07/28/2026 |
Joseph Catanzaro Mizuho Securities | Buy | Maintained | $120.00 | +25.6% | 07/13/2026 |
Tyler Van Buren TD Cowen | Buy | Maintained | - | - | 06/23/2026 |
Umer Raffat Evercore ISI | Buy | Maintained | - | - | 06/03/2026 |
Unknown Analyst Guggenheim | Buy | Reiterated | $115.00 | +20.4% | 05/06/2026 |
Martin Auster Raymond James | Buy | Initiated | $80.00 | -16.2% | 04/10/2026 |
Next call in 11 days
Fri, Nov 13, 4:00 PM
Fiscal period
Q3 2026
- Normalized EPS / Est. (USD)
- GAAP EPS / Est. (USD)
- / -$0.84
Revenue / Est. (USD)
- / 0.00
Fiscal Q3 2026 earnings call
youtube_liveWaiting for the earnings call
At a glance: upcoming earnings
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
- Quarterly
- Annual
All values in USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
Revenue | - | - | - | - |
Cost of goods sold | 45.25M | 44.64M | 60.41M | 65.50M |
Cost of revenue | 45.25M | 44.64M | 60.41M | 65.50M |
Research and development expenses | - | - | - | - |
Total research and development expenses | - | - | - | - |
Selling, general, and admin expenses | 11.64M | 12.53M | 15.23M | 16.14M |
Operating expense | 11.64M | 12.53M | 15.23M | 16.14M |
Total operating expenses | 56.89M | 57.17M | 75.64M | 81.64M |
Operating income | -56.89M | -57.17M | -75.64M | -81.64M |
Other non operating income | 40.33M | -12.50M | -30.36M | -4.61M |
EBT including unusual items | -11.18M | -62.53M | -69.00M | -36.20M |
EBT excluding unusual items | -11.18M | -62.53M | -99.00M | -76.20M |
Income tax expense | - | - | - | - |
Effective tax rate | - | - | - | - |
Other operating expenses | - | - | - | - |
Net income | -11.18M | -62.53M | -69.00M | -36.20M |
Net profit margin | - | - | - | - |
Earnings per share | -0.15 | -0.74 | -0.74 | -0.36 |
Interest and investment income | 5.38M | 7.14M | 7.00M | 10.05M |
Interest expense | - | - | - | - |
Net interest expenses | 5.38M | 7.14M | 7.00M | 10.05M |
Depreciation and amortization charges | - | - | - | - |
EBITDA | - | - | - | - |
Gain or loss from assets sale | - | - | -30.00M | -40.00M |
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider | Position | Type | Date | Shares | Amount |
|---|---|---|---|---|---|
Page 1
Upcoming events